Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock

Key Points

• Palvella Therapeutics COO Kathleen Goin sold 4,302 shares for $654,807 at an average price of $152.21 under a pre-arranged Rule 10b5-1 plan. Her remaining direct ownership fell 66.64% to 2,154 shares.
• PVLA shares declined 4.9% to $142.58, while the company reported a quarterly loss of $1.52 per share, missing analyst expectations of a $1.17 loss.
• Despite the insider sale and earnings miss, analysts maintain a consensus “Buy” rating with a $209.14 average price target; institutional investors own 40.11% of the stock.

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company's stock, valued at $327,860.34. This represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, June 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $110.73, for a total value of $476,360.46.

Palvella Therapeutics Trading Down 4.9%

Shares of NASDAQ:PVLA traded down $7.38 on Thursday, reaching $142.58. 208,989 shares of the company traded hands, compared to its average volume of 270,510. The stock has a market capitalization of $2.05 billion, a P/E ratio of -29.52 and a beta of -0.17. The business's 50-day simple moving average is $140.96 and its 200 day simple moving average is $123.87. Palvella Therapeutics, Inc. has a 52 week low of $48.65 and a 52 week high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). Sell-side analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on PVLA shares. HC Wainwright restated a "buy" rating and issued a $270.00 target price on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Stephens reissued an "overweight" rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Chardan Capital raised shares of Palvella Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Finally, Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $209.14.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $140,343,000. Summit Partners Public Asset Management LLC lifted its stake in shares of Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company's stock valued at $40,761,000 after purchasing an additional 354,525 shares during the period. Vanguard Group Inc. lifted its stake in shares of Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company's stock valued at $31,010,000 after purchasing an additional 330,847 shares during the period. State Street Corp boosted its position in shares of Palvella Therapeutics by 206.3% during the fourth quarter. State Street Corp now owns 420,462 shares of the company's stock valued at $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Palvella Therapeutics by 262.4% during the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company's stock valued at $40,558,000 after purchasing an additional 280,573 shares in the last quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source